Artiva Biotherapeutics (ARTV) Share-based Compensation (2023 - 2026)

Artiva Biotherapeutics (ARTV) has 4 years of Share-based Compensation data on file, last reported at $19.7 million in Q1 2026.

• On a quarterly basis, Share-based Compensation rose 4357.01% year-over-year to $19.7 million in Q1 2026; TTM through Mar 2026 was $19.7 million, a 227.46% increase from a year earlier, with the FY2025 full-year figure at $1.1 million, down 84.24% from the prior year.
• Share-based Compensation for Q1 2026 stood at $19.7 million, up from $7.4 million in the prior quarter.
• Over the last five years, Share-based Compensation for ARTV reached as high as $19.7 million in Q1 2026 and fell as low as $442000.0 in Q1 2025.
• Historically, Share-based Compensation has averaged $3.9 million across 4 years, with a median of $1.5 million in 2024.
• Across the five-year window, Share-based Compensation slumped 68.56% in 2025 and surged 4357.01% in 2026, its largest moves.
• Year by year, Share-based Compensation stood at $1.4 million in 2023, then surged by 56.9% to $2.2 million in 2024, then surged by 238.83% to $7.4 million in 2025, then soared by 166.22% to $19.7 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $19.7 million in Q1 2026, $7.4 million in Q3 2025, and $1.5 million in Q2 2025.